In this study, we first aimed to validate this ctDNA-Seq technology’s ability using a targeted 40 gene panel to identify mutations in 10 patients who initially showed RAS wild-type status in tumour tissue and either showed primary or acquired resistance when treated with EGFR-Ab therapy predominantly in combination with chemotherapy. The gene discussed is EGFR; the disease is neoplasm.